New markers for minimal residual disease detection in acute lymphoblastic leukemia. - Wikidata - wikimedia - TriplyDB

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q35067391

about

Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells Acute lymphoblastic leukaemia A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia?International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors A framework for regularized non-negative matrix factorization, with application to the analysis of gene expression data Cis-regulatory functions of overlapping HIF-1alpha/E-box/AP-1-like sequences of CD164.Adhesion GPCRs in Tumorigenesis.The CD300 molecules: an emerging family of regulators of the immune system.The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.Functional requirements for inhibitory signal transmission by the immunomodulatory receptor CD300a.Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients.An advanced fragment analysis-based individualized subtype classification of pediatric acute lymphoblastic leukemia.Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Natural killer cell therapy in children with relapsed leukemia.Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.Measurements of treatment response in childhood acute leukemia.Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia The expression and function of human CD300 receptors on blood circulating mononuclear cells are distinct in neonates and adults EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age.Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.In silico evidence of signaling pathways of notch mediated networks in leukemia.Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.Role of integrin alpha4 in drug resistance of leukemia Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.Potential therapeutic targets and small molecular drugs for pediatric B-precursor acute lymphoblastic leukemia treatment based on microarray data Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia.CD73-adenosine: a next-generation target in immuno-oncology.

P2860

Q24304296-EA0E3FE9-BF62-4A6C-8CCB-371337274A71 Q24602387-8E338AC9-8FF2-4AB8-B806-DCD217133503 Q26749571-F704C88C-C68D-4D80-A9B4-00F7A7A6A239 Q26751269-0D8C3123-742C-412D-B976-18CF2F71BE11 Q26766395-E141D330-415E-4B6E-B223-3FCD2226DDEA Q28257710-46E373FD-6160-420A-9DEE-B7BE216AFFC1 Q28278807-AA05CA87-CE35-4A62-84C8-621524966A11 Q31039180-0AEEB7D8-3D7C-462B-B9EC-982C7AFA8582 Q33558191-FC508344-FF1A-47DA-B95E-FB26DB8C040F Q34035020-2620BA6C-0EBF-4F57-AE62-C78B7B1A1A9D Q34235906-6A570001-2F8F-4339-B484-E43ADD733881 Q34248446-586DD624-C389-4DBB-927D-A326A57F2BF6 Q35245799-0F289148-7D2C-4271-B1F6-D93F69958548 Q35683329-1C971F07-CF73-47BE-8736-AAEB063A76C8 Q35869978-BEBDD463-883D-4369-B605-C1A15C656B97 Q36106034-B59996C7-BCBC-4257-BBA9-C9577C9A24FC Q36182008-C5506684-28AA-4FBD-BEE0-1EC67DC7613B Q36251948-EF68DB0C-D027-4CD0-9C97-B874CCB22A2A Q36371093-FEB03311-9ED0-43D0-9A47-8C94FD91BD97 Q36509641-93C7AC03-948B-406A-A332-AE4EF4D86672 Q36513773-E9FEA81F-3080-4443-B66A-482AC7F78D38 Q36781786-DBE3DC91-63C7-43C7-98D2-52FBD88073CC Q37148110-6A178625-46BB-4AFE-B379-02CE89C603D1 Q37232792-165128F9-D85E-4DBB-9AEB-115FD6819579 Q37555328-ABF5BB7E-1113-4BB7-9EE6-DD7A8E231861 Q37619915-D46014EA-C0E3-4F19-B648-A921F7CA41A2 Q37624584-937E8F9B-9D52-4BB2-A8E2-920EE4980711 Q37655004-29A1CB0A-1C2A-49D2-AEC0-B32F3D895B63 Q37696226-57F3A73E-DA14-499D-9B8B-F71F5DF8CD0A Q37989006-4470A524-78D7-4957-84EA-0BA8D3918801 Q38000087-00FD8376-BBAD-4A35-B7AF-30A7AFF6B829 Q38079288-A760B1D7-9713-477B-8023-6129A85AD90E Q38105123-F1486BDF-02EA-48A8-BB4E-D555ADA42AA1 Q38113738-A84C62EE-3CD4-484C-8FE7-D77911DAD25A Q38186870-F8A8EE9B-45C4-4372-B4FC-5AE29015C819 Q38218126-027A53B6-87F1-41B2-8304-46BAA7765BC0 Q38452047-48E11C85-9201-4BE9-8488-EC634A527762 Q38633676-4BA1507A-0B05-456D-A80C-E1E75C43FD5F Q38673618-A7D4B000-6E50-4CF7-9239-0CFBAE1A5827 Q38711094-22163968-3DB9-493E-94D2-67F45EFDDDF0

P2860

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q35067391

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

@ast

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

@en

type

label

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

@ast

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

@en

prefLabel

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

@ast

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

@en

P1433

Q35067391-BCCFEABE-C52A-47C9-9810-A6A88C6A2855

P1476

Q35067391-CB79B82E-0806-4BDD-B3F7-29F33E677264

P2093

Q35067391-0E87265E-6A4E-4EC7-91BB-046F470D58C9

Q35067391-150A3866-0CF9-4058-B999-0F0DCE2E9C7B

Q35067391-39FFAE33-13F9-4FC3-9745-A22959B62477

Q35067391-5537C448-90BB-470F-9193-136BF4938FB2

Q35067391-8BBBA69C-31CE-4764-A404-DA45FEF63008

Q35067391-A7E9FA51-EE96-4F2B-AFDA-1ABFB2213956

Q35067391-AD475579-E1A3-4FC8-B407-09FAC90E1BDF

Q35067391-BCDFD44A-5A8A-42F2-9D8A-7C728D34B2AE

Q35067391-CC6D245B-0773-4D33-99CF-D0B017543B37

Q35067391-EC634D4E-D88A-45F6-AF2E-38D5930D19E7

P2860

Q35067391-0FA7D5D9-9F62-4372-B49B-9906AC2A6524

Q35067391-1166F6DF-85C3-4F16-9414-4EA0CBDA30CB

Q35067391-20E9CB45-571A-4934-A1E1-FFC1E7CE58A8

Q35067391-23FB2FBD-B2A6-4504-8F76-59B9904E06FC

Q35067391-2833E172-F9F6-4216-8184-38D034EA52F6

Q35067391-34BB61FD-6DE3-41A2-B379-D91A77BAD3C0

Q35067391-3E4859B0-67D6-4D69-A4A8-AB04FC5EF7A9

Q35067391-43E5FD76-8C41-49C9-9B57-D37CC3E9A2F4

Q35067391-448FE26B-15B4-4131-8C23-B1C17B2B2361

Q35067391-4E1FA2D8-5B51-4708-8884-A296C68AA3F6

P304

Q35067391-1C9E05F1-37DD-4E29-9E5B-FCC693DCC354

P31

Q35067391-3B2C1C0B-EA9F-45EA-92C1-A056AD2859E8

P356

Q35067391-9AA73D79-33D1-4848-8A99-C7986D1BB059

P407

Q35067391-C971955E-C563-4564-AE60-8F76BB4E6888

P433

Q35067391-44FD74C3-70FA-4EC8-BEAC-8A96A12A64FB

P478

Q35067391-4FF892B9-4FDC-4026-912C-790455C632D3

P50

Q35067391-626A4BCC-32A8-46D5-B044-32593B791200

P577

Q35067391-EE622FE4-6990-426F-8E3C-6A78507E33B1

P5875

Q35067391-1ECD7436-7D66-410D-91C6-BDA818F5AC7D

P698

Q35067391-E8F0B5B0-5E6E-4CFD-8EC0-3FB567274264

P921

Q35067391-F370F64A-E539-4BE2-A9FD-F1BC0194CFE5

P932

Q35067391-C906B3FC-7EBB-43BF-A49D-DBE7C04807CC

P356

BLOOD-2010-12-324004

P1433

P1476

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

@en

P2093

Christopher Clark

http://www.w3.org/2001/XMLSchema#string

Dario Campana

http://www.w3.org/2001/XMLSchema#string

Elaine Coustan-Smith

http://www.w3.org/2001/XMLSchema#string

Guangchun Song

http://www.w3.org/2001/XMLSchema#string

James R Downing

http://www.w3.org/2001/XMLSchema#string

Laura Key

http://www.w3.org/2001/XMLSchema#string

Mohammad Mehrpooya

http://www.w3.org/2001/XMLSchema#string

Patricia Stow

http://www.w3.org/2001/XMLSchema#string

Peixin Liu

http://www.w3.org/2001/XMLSchema#string

Sheila Shurtleff

http://www.w3.org/2001/XMLSchema#string

P2860

Treating childhood acute lymphoblastic leukemia without cranial irradiation

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.

MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.

11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

P304

6267-6276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-12-324004

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51045766

http://www.w3.org/2001/XMLSchema#string

P698

21487112

http://www.w3.org/2001/XMLSchema#string

P921

P932

3122946

http://www.w3.org/2001/XMLSchema#string